Needham Reiterates Buy Rating on Establishment Labs Inc. (ESTA)

Needham analyst Mike Matson reiterated a Buy rating and $48.00 price target on Establishment Labs Inc. (NASDAQ: ESTA).

The analyst commented: "ESTA hosted an investor day on 6/12/25 in New York City. At the event, ESTA hosted three panels with plastic surgeon key opinion leaders (KOLs) focused on breast augmentation and breast reconstruction. The KOLs were very positive about ESTA's implants and procedures and expect ESTA to capture significant market share in the US within the next few years. ESTA management reiterated their 2025 guidance and indicated that its 2Q25 US revenue was likely to be above consensus and that they were not seeing a slowdown in international markets. Overall, we think that ESTA represents a rare small-cap med tech product cycle story and that its shares are attractively valued considering its growth potential and we reiterate our Buy rating."

For an analyst ratings summary and ratings history on Establishment Labs Inc. click here. For more ratings news on Establishment Labs Inc. click here.

Shares of Establishment Labs Inc. closed at $37.12 yesterday.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Liberty Global (LBTYA) Reiterated at Buy by Benchmark Ahead of Q2 Earnings
• Incyte (INCY) PT Raised to $112 at BMO Capital